SAN

82.86

+0.08%↑

UCB

267.9

+3.32%↑

SHL.DE

36.38

+0.61%↑

ARGX

643

+3.71%↑

VIE

33.23

+1.75%↑

SAN

82.86

+0.08%↑

UCB

267.9

+3.32%↑

SHL.DE

36.38

+0.61%↑

ARGX

643

+3.71%↑

VIE

33.23

+1.75%↑

SAN

82.86

+0.08%↑

UCB

267.9

+3.32%↑

SHL.DE

36.38

+0.61%↑

ARGX

643

+3.71%↑

VIE

33.23

+1.75%↑

SAN

82.86

+0.08%↑

UCB

267.9

+3.32%↑

SHL.DE

36.38

+0.61%↑

ARGX

643

+3.71%↑

VIE

33.23

+1.75%↑

SAN

82.86

+0.08%↑

UCB

267.9

+3.32%↑

SHL.DE

36.38

+0.61%↑

ARGX

643

+3.71%↑

VIE

33.23

+1.75%↑

Search

Imerys SA.

Закрыт

СекторЗдравоохранение

20.74 -2.45

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

20.5

Макс.

21.8

Ключевые показатели

By Trading Economics

Доход

-550M

-479M

Продажи

-130M

1.6B

P/E

Средняя по отрасли

12.55

56.063

Дивидендная доходность

3.55

Рентабельность продаж

-29.457

Сотрудники

14,878

EBITDA

-310M

-43M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+28.97% upside

Дивиденды

By Dow Jones

Дивидендная доходность

Средняя по отрасли

3.55%

2.45%

Следующий отчет о доходах

27 апр. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-371M

1.8B

Предыдущая цена открытия

23.19

Предыдущая цена закрытия

20.74

Новостные настроения

By Acuity

15%

85%

25 / 349 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Strong Bearish Evidence

Imerys SA. График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

31 мар. 2026 г., 23:31 UTC

Популярные акции

Stocks to Watch: Nike, RH, NCino

31 мар. 2026 г., 22:35 UTC

Отчет

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1 апр. 2026 г., 00:00 UTC

Приобретения, слияния, поглощения

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31 мар. 2026 г., 23:50 UTC

Приобретения, слияния, поглощения

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31 мар. 2026 г., 23:43 UTC

Обсуждения рынка

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31 мар. 2026 г., 23:33 UTC

Обсуждения рынка
Главные новостные события

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31 мар. 2026 г., 23:21 UTC

Отчет

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31 мар. 2026 г., 23:14 UTC

Обсуждения рынка
Отчет

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31 мар. 2026 г., 23:12 UTC

Обсуждения рынка

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31 мар. 2026 г., 22:36 UTC

Отчет

China Vanke 2025 Loss Widens >000002.SZ

31 мар. 2026 г., 22:36 UTC

Отчет

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31 мар. 2026 г., 22:36 UTC

Отчет

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31 мар. 2026 г., 22:36 UTC

Отчет

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31 мар. 2026 г., 22:36 UTC

Отчет

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31 мар. 2026 г., 21:46 UTC

Приобретения, слияния, поглощения

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31 мар. 2026 г., 21:36 UTC

Обсуждения рынка

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31 мар. 2026 г., 21:35 UTC

Отчет

Nike Expects China Sales Down 20% in 4Q, CFO Says

31 мар. 2026 г., 21:35 UTC

Отчет

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31 мар. 2026 г., 21:35 UTC

Отчет

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31 мар. 2026 г., 21:33 UTC

Приобретения, слияния, поглощения

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31 мар. 2026 г., 21:33 UTC

Отчет

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31 мар. 2026 г., 21:32 UTC

Отчет

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31 мар. 2026 г., 21:28 UTC

Отчет

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31 мар. 2026 г., 21:26 UTC

Отчет

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31 мар. 2026 г., 21:25 UTC

Отчет

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31 мар. 2026 г., 21:24 UTC

Обсуждения рынка
Отчет

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31 мар. 2026 г., 21:22 UTC

Отчет

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31 мар. 2026 г., 21:22 UTC

Отчет

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31 мар. 2026 г., 21:21 UTC

Отчет

Nike's Digital Channel Still Too Promotional, CFO Says

31 мар. 2026 г., 21:20 UTC

Отчет

Nike CEO: Converse Remains Important to Portfolio

Сравнение c конкурентами

Изменение цены

Imerys SA. Прогноз

Целевая цена

By TipRanks

28.97% рост

Прогноз на 12 месяцев

Средняя 27.6 EUR  28.97%

Максимум 32.2 EUR

Минимум 23 EUR

Основано на мнении 2 аналитиков Wall Street, спрогнозировавших целевые цены для Imerys SA. на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

2 ratings

1

Покупка

1

Удержание

0

Продажа

Техническая оценка

By Trading Central

29.06 / 30.24Поддержка и Сопротивление

Краткосрочная

Strong Bearish Evidence

Среднесрочная

Bullish Evidence

Долгосрочная

Bearish Evidence

Настроения

By Acuity

25 / 349Рейтинг в Здравоохранение

Новостные настроения

Сильные свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Выше среднего

Финансовые показатели

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Imerys SA.

Imerys S.A. provides mineral-based specialty solutions for various industries worldwide. The company provides additives for paints, coatings, adhesives, caulks, sealants, and rubber; minerals for technical ceramics and traditional ceramics; functional additives for plastics and thermoset; high-performance binders for dry mix mortars and floor screeds; fillers and coatings for paper, board, and packaging applications; filtration agents for liquids and blood plasma; pharmaceutical diluents, coloring agents, processing aids, glidants, and lubricants for tablet production; engineered minerals for cosmetic industry; food additives to preserve flavor; coating agents to improve fertilizer fow; mineral-based cat litters; alumina for high-performance abrasives and graphite in brake pads; and carbon black for conductivity in onboard data systems. The company also offers minerals used to produce high purity silicon metal for electronics and solar panels; graphite and carbon-based solutions for industrial applications; mineral solutions for batteries and energy storage; refractory minerals and solutions for high-temperature processes; and alumina and zirconia for abrasives. It serves construction and infrastructure, consumer and health care, automotive and transportation, energy and electronics, and industry and equipment industries. The company was incorporated in 1880 and is headquartered in Paris, France. The company is a subsidiary of Belgian Securities BV.
help-icon Live chat